VVOS · Vivos Therapeutics, Inc.

The convertible preferred stock is convertible at any time, at the holder's election, subject to a beneficial ownership limitation, and has no expiration date.

Michael C. Skaff serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 4 LLC. Michael C. Skaff and SP Manager LLC disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose.

On June 30, 2026, V-Co Investors 4 LLC converted a bridge promissory note in the amount of $1,000,000 entered into between the reporting person and the Issuer into shares of the Issuer's Series A Convertible Preferred Stock, based on $0.456 per share plus $0.125 per share in accordance with the Nasdaq minimum price rules.

The convertible preferred stock is convertible at any time, at the holder's election, subject to a beneficial ownership limitation, and has no expiration date.

Michael C. Skaff serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 4 LLC. Michael C. Skaff and SP Manager LLC disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose.

Michael C. Skaff serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 4 LLC. Michael C. Skaff and SP Manager LLC disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose.

Michael C. Skaff serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 3 LLC. Michael C. Skaff and SP Manager LLC disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose.

Michael C. Skaff serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 3 LLC. Michael C. Skaff and SP Manager LLC disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose.

Michael C. Skaff serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 3 LLC. Michael C. Skaff and SP Manager LLC disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose.

The Pre-Funded Warrant has a term ending on the complete exercise of the Pre-Funded Warrant.

Michael C. Skaff serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 3 LLC. Michael C. Skaff and SP Manager LLC disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose.

On March 31, 2026, V-Co Investors 3, LLC converted a bridge promissory note in the amount of $1,400,000 entered into between the reporting person and the Issuer into shares of the Issuer's common stock, based on $1.09 per share of Common Stock plus $0.25 per share in accordance with the Nasdaq minimum price rules.

Michael C. Skaff serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 3 LLC. Michael C. Skaff and SP Manager LLC disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose.

On September 7, 2024 (the "Grant Date"), the Reporting Person received a grant of 315,421 stock options, which grant was made under but subject to stockholder approval of the Issuer's 2024 Omnibus Equity Incentive Plan and such grant at the Issuer's 2024 Annual Meeting. Such meeting was held, and such stockholder approval was obtained, on November 26, 2024. One-third shall vest and become exercisable in three installments on each of the first, second and third anniversaries of the date of grant through September 7, 2027.

On September 7, 2024 (the "Grant Date"), the Reporting Person received a grant of 180,533 stock options, which grant was made under but subject to stockholder approval of the Issuer's 2024 Omnibus Equity Incentive Plan and such grant at the Issuer's 2024 Annual Meeting. Such meeting was held, and such stockholder approval was obtained, on November 26, 2024. Stock options shall vest and become exercisable in three installments subject to achievement of the following three performance metrics: (1) quarter over quarter revenue growth of at least 15% over the same prior year quarter, (2) total stockholder return from date of grant, and (3) positive cash flow for two consecutive quarters.

On June 20, 2024, the Reporting Person received a grant of 4,000 stock options from the Issuer. One-half vested immediately, one-fourth will vest on September 30, 2024 and one-fourth will vest on December 31, 2024.

On June 20, 2024 (the "Grant Date"), the Reporting Person received a grant of 15,000 stock options from the Issuer. One-fifth vested immediately and one-fifth will vest annually on each anniversary of the Grant Date through June 20, 2028.

On June 20, 2024, the Reporting Person received a grant of 4,000 stock options from the Issuer. One-half vested immediately, one-fourth will vest on September 30, 2024 and one-fourth will vest on December 31, 2024.

On June 20, 2024 (the "Grant Date"), the Reporting Person received a grant of 20,000 stock options from the Issuer. One-fifth vested immediately and one-fifth will vest annually on each anniversary of the Grant Date through June 20, 2028.

On June 20, 2024, the Reporting Person received a grant of 4,000 stock options from the Issuer. One-half vested immediately, one-fourth will vest on September 30, 2024 and one-fourth will vest on December 31, 2024.

On June 20, 2024, the Reporting Person received a grant of 4,000 stock options from the Issuer. One-half vested immediately, one-fourth will vest on September 30, 2024 and one-fourth will vest on December 31, 2024.

On June 20, 2024, the Reporting Person received a grant of 4,000 stock options from the Issuer. One-half vested immediately, one-fourth will vest on September 30, 2024 and one-fourth will vest on December 31, 2024.

Shares held by Coronado V Partners, LLC, of which the reporting person is a member and manager.

30,000 stock options granted on December 23, 2022. One-half vested immediately and one-eighth vests quarterly every three months through December 23, 2023.

30,000 stock options granted on December 23, 2022. One-half vested immediately and one-eighth vests quarterly every three months through December 23, 2023.

30,000 stock options granted on December 23, 2022. One-half vested immediately and one-eighth vests quarterly every three months through December 23, 2023.

150,000 stock options granted on December 23, 2022. One-fifth vested immediately and one-fifth vests annually on each anniversary date through December 23, 2026.

30,000 stock options granted on December 23, 2022. One-half vested immediately and one-eighth vests quarterly every three months through December 23, 2023.

30,000 stock options granted on December 23, 2022. One-half vested immediately and one-eighth vests quarterly every three months through December 23, 2023.

200,000 stock options granted on December 23, 2022. One-fifth vests annually on each anniversary date through December 23, 2026.

333,334 fully vested stock options granted on December 23, 2022.

The price reported in Column 4 is a weighted average price. These shares were purchased in four separate transactions ranging from $2.02 to $2.035 on May 31, 2022. The reporting person undertakes to provide to Vivos Therapeutics, Inc., any security holder of Vivos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.

125,000 stock options granted on February 25, 2022. One-fifth vested immediately and one-fifth vests annually on each anniversary date through February 25, 2026.

50,000 stock options granted on February 25, 2022. One-fifth vested immediately and one-fifth vests annually on each anniversary date through February 25, 2026.

50,000 stock options granted on August 31, 2021. One-fifth vested immediately and one-fifth vests annually on each anniversary date through August 31, 2025.

30,000 stock options granted on August 5, 2021. One-half vested immediately and one-eighth vests quarterly every three months through August 5, 2022.

30,000 stock options granted on August 5, 2021. One-half vested immediately and one-eighth vests quarterly every three months through August 5, 2022.

30,000 stock options granted on August 5, 2021. One-half vested immediately and one-eighth vests quarterly every three months through August 5, 2022.

30,000 stock options granted on August 5, 2021. One-half vested immediately and one-eighth vests quarterly every three months through August 5, 2022.

30,000 stock options granted on August 5, 2021. One-half vested immediately and one-eighth vests quarterly every three months through August 5, 2022.

30,000 stock options granted on August 5, 2021. One-half vested immediately and one-eighth vests quarterly every three months through August 5, 2022.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.335 to $5.40.

100,000 stock options granted on March 12, 2021. One-fifth vested immediately and one-fifth vests annually on each anniversary date through March 12, 2025.

100,000 stock options granted on March 12, 2021. One-fifth vested immediately and one-fifth vests annually on each anniversary date through March 12, 2025.

1,000 shares purchased in prices ranging from $7.25 through $7.2798 per share.